WO2001037862A2 - A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias - Google Patents

A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias Download PDF

Info

Publication number
WO2001037862A2
WO2001037862A2 PCT/HU2000/000122 HU0000122W WO0137862A2 WO 2001037862 A2 WO2001037862 A2 WO 2001037862A2 HU 0000122 W HU0000122 W HU 0000122W WO 0137862 A2 WO0137862 A2 WO 0137862A2
Authority
WO
WIPO (PCT)
Prior art keywords
lactobacilli
prostate
hyperplasias
vaccine
inflammation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HU2000/000122
Other languages
French (fr)
Other versions
WO2001037862A3 (en
Inventor
Gyula Árpád VARGA
Erika Ágnes LÁZÁR
József BARTUS
Károly ÚJHELYI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ujhelyi Ottilia
Ujhelyi Tamas Karoly
VAKCINA KFT
Original Assignee
Ujhelyi Ottilia
Ujhelyi Tamas Karoly
VAKCINA KFT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00981507A priority Critical patent/EP1272216B1/en
Priority to CA2394843A priority patent/CA2394843C/en
Priority to AT00981507T priority patent/ATE470452T1/en
Priority to SI200020063A priority patent/SI20960B/en
Priority to AU18741/01A priority patent/AU779214B2/en
Priority to SK738-2002A priority patent/SK288132B6/en
Priority to DK00981507.7T priority patent/DK1272216T3/en
Priority to DE60044539T priority patent/DE60044539D1/en
Priority to EA200200602A priority patent/EA005198B1/en
Priority to ROA200200663A priority patent/RO122760B1/en
Priority to PL355886A priority patent/PL201804B1/en
Application filed by Ujhelyi Ottilia, Ujhelyi Tamas Karoly, VAKCINA KFT filed Critical Ujhelyi Ottilia
Priority to IL14977900A priority patent/IL149779A0/en
Priority to UA2002064624A priority patent/UA78673C2/en
Publication of WO2001037862A2 publication Critical patent/WO2001037862A2/en
Publication of WO2001037862A3 publication Critical patent/WO2001037862A3/en
Priority to IL149779A priority patent/IL149779A/en
Anticipated expiration legal-status Critical
Priority to US12/077,780 priority patent/US20080175865A1/en
Priority to US13/049,344 priority patent/US9056073B2/en
Priority to US14/735,637 priority patent/US20160051657A1/en
Priority to US15/891,620 priority patent/US20180161414A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Definitions

  • a vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
  • the present invention relates to a vaccine comprising lactobacilli useful in treating prostate inflammation and benign prostate hyperplasias (stages I and II).
  • K. Ujhelyi has found that necrosis can be induced also by Lactobacillus strains cultivated from vagina. Based on his observation it can be stated that the body of the bacterium contains a toxin which is responsible for damaging the epithelia [Ujhelyi K. et al. : Role of Lactobacillus in urogenital inflammations and their treatment with vaccination, Symposium cum participatione internationalis de Biocenosi Vaginae, Smolenie, 1983]. Certain strains injected intradermal to the back of rabbits cause necrosis of smaller or larger area, while others cause necrosis only in higher concentration or do not cause necrosis at all. K. Ujhelyi has found that rabbits can be immunised by vaccination against the necrotic effect.
  • Trichomonas vaginalis contributes to the raising of vaginal pH by consuming lactic acid produced by lactobacilli in the vagina, thereby promotes the over-proliferation of lactobacilli, consequently the produced toxin is present in higher concentration which, by damaging mucous membrane, causes cell necrosis.
  • lactobacilli because of their receptor inhibiting and antibiotic activity as well as pH-modifying effect, are antagonistic to pyogenic microorganisms [Reddy et al : Natural antibiotic activity of Lactobacillus, Dairy Prod J.,
  • lactobacilli can bind directly to T-lymphocytes since both the T-helper and T-killer cells have specific receptors for lactobacilli. Furthermore, lactobacilli promote the gamma-interferon production of the lymphocytes and the cytotoxic activity of the natural killer cells [De Simone C. et al. : Enhancement of immune response of murine Peyer's pothes by a diet supplemented with yoghurt, J.
  • lactobacilli show antitumour and macrophage-activating activity [Kato I. et al. : Antitumor activity of Lactobacillus casei in mice, Gann, 72:517-523 (1983); Oda M. et al . Antitumor polysaccharide from
  • the inventors of the present invention have, however, found that the conditions in prostate are favourable to the proliferation of lactobacilli and that pathogenic lactobacilli can often be cultivated from patients suffering from chronic prostate inflammation and/or prostate hyperplasia. On this basis the inventors therapeutic utilization of vaccines comprising lactobacilli for treating such patients has been worked out.
  • the invention relates to vaccines for treating prostate inflammations and benign prostate hyperplasias (stages I and II) comprising lactobacilli in inactivated form and carriers and/or excipients commonly used in vaccine preparations.
  • the invention relates to the use of lactobacilli for producingvaccines capable of treating prostate inflammation and benign prostate hyperplasias (stages I and II).
  • the invention relates to the use of lactobacilli for treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II).
  • the invention relates to a method of treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II) comprising administering intramuscularly an effective dose of a strain-suspension of lactobacilli to a patient in need of such treatment.
  • the strain-suspension of lactobacilli comprises a mixed population of the said lactobacilli in inactivated form.
  • the lactobacilli used in the vaccine of the invention are Lactobacillus strains used in the above-said vaccines Gynevac ⁇ , Gyantren ⁇ and SolcoTrichovac (R) that previously have been cultivated from women suffering from gynaecologic inflammations of bacterial origin.
  • the single cultivated strains can be used per se or in the form of a blend of the strains.
  • the vaccine of the invention can be produced by methods commonly used for preparing vaccines.
  • the cultivated strains are stored in lyophilised form, then, before use, they are propagated by culturing in Man-Rogosa-Sharpe medium at 45 °C.
  • composition of the said medium and the preparation method are set forth below. To 2300 ml of sterile water the following components are added sequentially, after dissolving the previously added component:
  • the obtained solution is adjusted to 3000 ml by the addition of sterile water, filtered on G4 filter, bottled in smaller volumes and sterilized at 121 °C.
  • composition of the above-said salt solution is as follows: 28.75 g of MgSO 4 -7H 2 O, 6 g of MnSO 4 -2H 2 O and 1.7 of FeSO 4 -7H 2 O dissolved in 250 ml of sterile water.
  • the protein content of the vaccine (suspension) of the invention is at least 0.08 mg/ml, and may be up to 1 mg/ml or more, preferably from about 0.08 to about 0.32 mg/ml, more preferably about 0.16 mg/ml.
  • the used dose of the vaccine of the invention and the frequency of the administration depend on the conditions of the patient and the severity of the symptoms to be treated.
  • the precise dose and frequency of administration should be specified by the practitioning physician. According to our experiences it is advantageous if during a cure the vaccine is administered intramuscularly in a volume of 1 ml, once weekly, altogether 5 times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to vaccines for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising lactobacilli in an inactivated form and carriers and/or excipients commonly used in vaccine preparations.

Description

A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
FIELD OF THE INVENTION
The present invention relates to a vaccine comprising lactobacilli useful in treating prostate inflammation and benign prostate hyperplasias (stages I and II).
BACKGROUND OF THE INVENTION
The pathogenecity of certain lactobacilli has been reported in 1938 [F. Marshall: Der Dόderleinische Bacillus vaginalis als Endokarditiserreger, Zentr. Bad. Parasit. Kde. I. Abt. Orig., 141: 153-159 (1938); E. Biocca es A. Sepilli: Human infections caused by lactobacilli, J. Inf. Dis., 81:112-115 (1947); W. Sims: A pathogenic Lactobacillus, J. Path. Bact, 87:99-105 (1964); B. Rosan and B. F. Hammond: Toxicity of Lactobacillus casei, J. Dent. Res., 44:783-787 (1965); M. E. Sharpe, L. R. Hill and S. P. Lapage: Pathogenic lactobacilli, J. Med., Microbiol, 6, 281-286 (1973).
G. Wied reported in 1952 [Zbl. Bact., 160:413 (1952)] that certain Lactobacillus strains show mucous membrane damaging activity. Rosan and Hammond [1965, ibid] reported that, in case of Lactobacillus strains strongly pathogenic to mice, intradermal inoculation of bacteria both in living and in thermally inactivated state causes necrosis on the back of rabbits.
K. Ujhelyi has found that necrosis can be induced also by Lactobacillus strains cultivated from vagina. Based on his observation it can be stated that the body of the bacterium contains a toxin which is responsible for damaging the epithelia [Ujhelyi K. et al. : Role of Lactobacillus in urogenital inflammations and their treatment with vaccination, Symposium cum participatione internationalis de Biocenosi Vaginae, Smolenie, 1983]. Certain strains injected intradermal to the back of rabbits cause necrosis of smaller or larger area, while others cause necrosis only in higher concentration or do not cause necrosis at all. K. Ujhelyi has found that rabbits can be immunised by vaccination against the necrotic effect. He vaccinated rabbits intramuscularly with vaccine produced from certain Lactobacillus strains, 6 weeks later he administered intradermally cell-suspensions prepared from strains that have been shown previously to be necrotic, and observed that necrosis was not caused or was only caused in a lesser degree than in case of non-vaccinated rabbits.
Furthermore, K. Ujhelyi has found that Trichomonas vaginalis contributes to the raising of vaginal pH by consuming lactic acid produced by lactobacilli in the vagina, thereby promotes the over-proliferation of lactobacilli, consequently the produced toxin is present in higher concentration which, by damaging mucous membrane, causes cell necrosis.
Furthermore, it is known that lactobacilli, because of their receptor inhibiting and antibiotic activity as well as pH-modifying effect, are antagonistic to pyogenic microorganisms [Reddy et al : Natural antibiotic activity of Lactobacillus, Dairy Prod J.,
18: 15-22 (1983); Salminen et al : Lactic acid bacteria in the gut in normal and disorded states, Dig. Dis., 10:227-238 (1992)].
Recently it has been shown that lactobacilli can bind directly to T-lymphocytes since both the T-helper and T-killer cells have specific receptors for lactobacilli. Furthermore, lactobacilli promote the gamma-interferon production of the lymphocytes and the cytotoxic activity of the natural killer cells [De Simone C. et al. : Enhancement of immune response of murine Peyer's pothes by a diet supplemented with yoghurt, J.
Immunopharmacol, 1:87-95 (1987)]. It has been shown, furthermore, that lactobacilli aspecifically increase the production of IgM and IgG [Blocksma et al. : Adjuvant activity of lactobacilli, different effects of viable and killed bacteria, Clin. Exp. Immunol, 37:367-
373]. Additionally, under experimental conditions lactobacilli show antitumour and macrophage-activating activity [Kato I. et al. : Antitumor activity of Lactobacillus casei in mice, Gann, 72:517-523 (1983); Oda M. et al . Antitumor polysaccharide from
Lactobacillus sp., Agric Biol. Chem., 47: 1623-1627 (1983)]. H. Ruttgers has found that immunostimulation by lactobacilli causes a significant long-lasting raise of secretory immunoglobulin level in the vagina [Bacterial vaginitis: Protection against infection and secretory immunoglobulin levels in the vagina after immunization therapy with Gynatren,
Gynecol Obstet Invest., 26:240-249 (1988)].
Ujehelyi et al. [1983, ibid.] used parenterally lactobacilli for aspecific immunostimulation and observed that the used lactobacilli, in contrast to other aspecific immunostimulation (e.g. by BCG, endotoxins etc.), show protective effect against certain bacterial toxins. This applies especially to toxic lactobacilli.
In trials carried out with vaccines (Gynevac^, Gynatren^', SolcoTrichovac01') made of strains cultured by Ujhelyi it has been demonstrated that immunostimulation by lactobacilli, in contrast to other therapeutic treatments, restores the biological balance of the vagina, normalizes the pH, decreases the number of pathogenic bacteria and contributes to the propagation of Dόderlein-flora (a mixed population of lactobacilli capable of being cultivated from vagina). Nowadays it is an accepted fact that inflammatory diseases of the vagina caused by bacterial and Trichomonas infections can be cured in this way more successfully than by other therapy, on the one hand, and that such inflammatory conditions are the most important reason of premature births, on the other hand. Therefore, the frequency of premature births can also be decreased by such therapy [see e.g. in Genitalinfektion der Frau (SolcoTrichovac/Gynatren), Geburtsch. u. Frauenheil , 44:311 (1984); E. Lazar, Gy. Varga, I. Institoris and K. Ujhelyi: Investigating the factors, especially vaccination with lactobacilli, influencing the premature births, in Kazincbarcika (in Hungarian), Magyar Nδorvosok Lapja (Journal of Hungarian Gynaecologists), 51:353-356 (1986); E. Lazar, Gy. Varga, I. Institoris and K. Ujhelyi: Decreasing the ratio of neonates with small weight by lactobact vaccination of pregnant women (in Hungarian), Orvosi Hetilap (Physicians Weekly), 37:2263-2268 (1981); Ruttgers, 1988. ibid.; K. Ujhelyi, Gy. Philipp, Gy. Plank and V. Sagi: The Trichomonas syndrome I (in Hungarian), Magyar Nδorvosok Lapja (Journal of Hungarian Gynaecologists), 36:433-442 (1973); Sharon et al, New England Journal, December 28, 1995.]
More than 50 % of men aged 50 or more suffer from prostate hyperplasia and/or prostate inflammation. In spite of numerous kind of known and utilized therapies these patients are in need of medical treatment which is often unsuccessful. Taking into consideration the known and generally accepted pathogenesy, it could not be supposed that such diseases can be healed with vaccines comprising lactobacilli successfully.
The inventors of the present invention have, however, found that the conditions in prostate are favourable to the proliferation of lactobacilli and that pathogenic lactobacilli can often be cultivated from patients suffering from chronic prostate inflammation and/or prostate hyperplasia. On this basis the inventors therapeutic utilization of vaccines comprising lactobacilli for treating such patients has been worked out.
DISCLOSURE OF THE INVENTION The invention relates to vaccines for treating prostate inflammations and benign prostate hyperplasias (stages I and II) comprising lactobacilli in inactivated form and carriers and/or excipients commonly used in vaccine preparations.
In another aspect the invention relates to the use of lactobacilli for producingvaccines capable of treating prostate inflammation and benign prostate hyperplasias (stages I and II).
In a furterther aspect the invention relates to the use of lactobacilli for treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II).
Furthermore, the invention relates to a method of treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II) comprising administering intramuscularly an effective dose of a strain-suspension of lactobacilli to a patient in need of such treatment.
In a preferable enbodiment of the method of the invention the strain-suspension of lactobacilli comprises a mixed population of the said lactobacilli in inactivated form. The lactobacilli used in the vaccine of the invention are Lactobacillus strains used in the above-said vaccines Gynevac^, Gyantren^ and SolcoTrichovac(R) that previously have been cultivated from women suffering from gynaecologic inflammations of bacterial origin. The single cultivated strains can be used per se or in the form of a blend of the strains. The vaccine of the invention can be produced by methods commonly used for preparing vaccines. Advantageously, the cultivated strains are stored in lyophilised form, then, before use, they are propagated by culturing in Man-Rogosa-Sharpe medium at 45 °C.
The composition of the said medium and the preparation method are set forth below. To 2300 ml of sterile water the following components are added sequentially, after dissolving the previously added component:
Bactotripton (Reanal) 30 g
Lablemko (Reanal) 30 g
K2HPO4 6 g triammonium citrate 6 g sodium acetate 15 g glucose 30 g lactose 30 g maltose 9 g yeast extract (Reanal) 15 g
Tween 80 3 ml salt solution (composition see below) 15 ml
The obtained solution is adjusted to 3000 ml by the addition of sterile water, filtered on G4 filter, bottled in smaller volumes and sterilized at 121 °C.
The composition of the above-said salt solution is as follows: 28.75 g of MgSO4-7H2O, 6 g of MnSO4-2H2O and 1.7 of FeSO4-7H2O dissolved in 250 ml of sterile water.
After culturing the cells are harvested by centrifuging, the pellet is suspended in physiological saline solution and treated with formaldehyde. The inactivated cells are harvested and resuspended in physiological saline solution. The level of dilution is adjusted on the basis of the protein content of the suspension. The protein content of the vaccine (suspension) of the invention is at least 0.08 mg/ml, and may be up to 1 mg/ml or more, preferably from about 0.08 to about 0.32 mg/ml, more preferably about 0.16 mg/ml.
The used dose of the vaccine of the invention and the frequency of the administration depend on the conditions of the patient and the severity of the symptoms to be treated. The precise dose and frequency of administration should be specified by the practitioning physician. According to our experiences it is advantageous if during a cure the vaccine is administered intramuscularly in a volume of 1 ml, once weekly, altogether 5 times.
The following example is given for the purpose of illustration of the invention without the intention of limiting of the scope claimed.
EXAMPLE
Investigations were carried out with the vaccine of the invention by administering same to patients with a diagnosis of prostate inflammation and/or prostate hyperplasias (stages I and II). The patients were adminstered intramuscularly 1 ml of a vaccine comprising lactobacilli of the invention once weekly for 5 weeks, whithout any other medical treatment. The results of the control examination carried out after this cure are summarised in the following Tables.
Number of the treated patients: 127 Diagnosis: prostate hyperplasia stages I and II
Figure imgf000008_0001
Number of the treated patients: 168 Diagnosis: prostate inflammation
Figure imgf000008_0002
As can be seen in the above Tables, a significant ratio of the patiens were healed or their conditions improved essentially.

Claims

Claims
1. A vaccine for treating prostate inflammation and benign prostate hyperplasias (stages I and II) comprising lactobacilli in inactivated form and carriers and/or excipients commonly used in vaccine preparations.
2. Use of lactobacilli for producing vaccines capable of treating prostate inflammations and benign prostate hyperplasias (stages I and II).
3. Use of lactobacilli for treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II).
4. A method of treating patients suffering from prostate inflammation and benign prostate hyperplasias (stages I and II) comprising administering intramuscularly an effective dose of a suspension of Lactobacillus strains to a patient in need of such treatment.
5. A method of claim 4 wherein the suspension of Lactobacillus strains comprises a mixed population of the said Lactobacillus strains in an inactivated form.
PCT/HU2000/000122 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias Ceased WO2001037862A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
PL355886A PL201804B1 (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
AT00981507T ATE470452T1 (en) 1999-11-25 2000-11-23 VACCINE CONTAINING LACTOBACILLI FOR THE TREATMENT OF INFLAMMATION OF THE PROSTATE AND BENIGN PROSTATE HYPERPLASIA
SI200020063A SI20960B (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
AU18741/01A AU779214B2 (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
SK738-2002A SK288132B6 (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
DK00981507.7T DK1272216T3 (en) 1999-11-25 2000-11-23 Vaccine comprising lactobacilli for the treatment of inflammation of the prostate and benign prostatic hyperplasia
IL14977900A IL149779A0 (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
CA2394843A CA2394843C (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
ROA200200663A RO122760B1 (en) 1999-11-25 2000-11-23 Vaccine for treating prostate inflammation and benign prostate hyperplasias and use of lactobacilli therefor
EP00981507A EP1272216B1 (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
EA200200602A EA005198B1 (en) 1999-11-25 2000-11-23 Vaccine for treating prostate inflammation and benign prostate hyperplasias based on lactobacilli and method for treating said diseases
DE60044539T DE60044539D1 (en) 1999-11-25 2000-11-23 VACCINATES CONTAINING LACTOBACILLI FOR THE TREATMENT OF PROSTATE INFLAMMATION AND PROSTATE HYPERPLASIA
UA2002064624A UA78673C2 (en) 1999-11-25 2000-11-23 Use of lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
IL149779A IL149779A (en) 1999-11-25 2002-05-21 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias and its production
US12/077,780 US20080175865A1 (en) 1999-11-25 2008-03-21 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
US13/049,344 US9056073B2 (en) 1999-11-25 2011-03-16 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
US14/735,637 US20160051657A1 (en) 1999-11-25 2015-06-10 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias
US15/891,620 US20180161414A1 (en) 1999-11-25 2018-02-08 Vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9904408A HU227086B1 (en) 1999-11-25 1999-11-25 Lactobacillus vaccine for treating prostata inflammatory and benign prostata hyperplasia
HUP9904408 1999-11-25

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10130823 A-371-Of-International 2002-09-16
US12/077,780 Continuation US20080175865A1 (en) 1999-11-25 2008-03-21 Vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias

Publications (2)

Publication Number Publication Date
WO2001037862A2 true WO2001037862A2 (en) 2001-05-31
WO2001037862A3 WO2001037862A3 (en) 2001-11-22

Family

ID=90014600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2000/000122 Ceased WO2001037862A2 (en) 1999-11-25 2000-11-23 A vaccine comprising lactobacilli for treating prostate inflammation and benign prostate hyperplasias

Country Status (20)

Country Link
US (4) US20080175865A1 (en)
EP (1) EP1272216B1 (en)
AT (1) ATE470452T1 (en)
AU (1) AU779214B2 (en)
CA (1) CA2394843C (en)
CZ (1) CZ302662B6 (en)
DE (1) DE60044539D1 (en)
DK (1) DK1272216T3 (en)
EA (1) EA005198B1 (en)
ES (1) ES2348591T3 (en)
HU (1) HU227086B1 (en)
IL (2) IL149779A0 (en)
PL (1) PL201804B1 (en)
PT (1) PT1272216E (en)
RO (1) RO122760B1 (en)
RS (1) RS51201B (en)
SI (1) SI20960B (en)
SK (1) SK288132B6 (en)
UA (1) UA78673C2 (en)
WO (1) WO2001037862A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723965A1 (en) * 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
WO2009027753A1 (en) 2007-08-27 2009-03-05 Feher Janos Composition and method inhibiting inflammation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
JP2020522479A (en) 2017-06-02 2020-07-30 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ Methods for making personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
JP7303811B2 (en) * 2017-12-19 2023-07-05 デュポン ニュートリション バイオサイエンシーズ エーピーエス Probiotics for Cognitive and Mental Health
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH639280A5 (en) * 1977-12-23 1983-11-15 Solco Basel Ag METHOD FOR PRODUCING A VACCINE AGAINST TRICHOMONAS SYNDROME.
DE19522472C2 (en) * 1995-06-21 1998-07-02 Eugen Baumgaertner Manufacturing process of a fermentation product for the treatment of prostate disorders
GB2338245B (en) * 1997-08-21 2001-11-21 New Zealand Dairy Board Immunity enhancing lactic acid bacteria
IT1298918B1 (en) * 1998-02-20 2000-02-07 Mendes Srl USE OF ARGININE DEIMINASE BACTERIA TO INDUCE APOPTOSIS AND / OR REDUCE AN INFLAMMATORY REACTION AND PHARMACEUTICAL COMPOSITIONS
IT1306716B1 (en) * 1999-06-21 2001-10-02 Mendes S U R L ASSOCIATION OF LACTIC BACTERIA AND ITS USE FOR THE PREVENTION AND / OR THERAPEUTIC TREATMENT OF INFECTIONS AND INFLAMMATORY STATES.

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723965A1 (en) * 2005-05-18 2006-11-22 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
WO2006123230A3 (en) * 2005-05-18 2007-03-15 Stallergenes Sa Compositions for antigen-specific induction of immuno-tolerance via oral immunization
US9555102B2 (en) 2005-05-18 2017-01-31 Stallergenes Compositions for antigen-specific induction of tolerance
US10610586B2 (en) 2005-05-18 2020-04-07 Stallergenes Compositions for antigen-specific induction of tolerance
WO2009027753A1 (en) 2007-08-27 2009-03-05 Feher Janos Composition and method inhibiting inflammation

Also Published As

Publication number Publication date
US20180161414A1 (en) 2018-06-14
SK7382002A3 (en) 2002-11-06
US9056073B2 (en) 2015-06-16
HUP9904408D0 (en) 2000-01-28
EA005198B1 (en) 2004-12-30
PL201804B1 (en) 2009-05-29
WO2001037862A3 (en) 2001-11-22
US20110243990A1 (en) 2011-10-06
SI20960B (en) 2011-01-31
ES2348591T3 (en) 2010-12-09
DK1272216T3 (en) 2010-09-27
DE60044539D1 (en) 2010-07-22
IL149779A (en) 2009-05-04
CA2394843C (en) 2011-01-18
UA78673C2 (en) 2007-04-25
PL355886A1 (en) 2004-05-31
HUP9904408A2 (en) 2002-03-28
RO122760B1 (en) 2010-01-29
ATE470452T1 (en) 2010-06-15
SK288132B6 (en) 2013-10-02
HU227086B1 (en) 2010-06-28
EP1272216B1 (en) 2010-06-09
EA200200602A1 (en) 2002-10-31
IL149779A0 (en) 2002-11-10
EP1272216A2 (en) 2003-01-08
SI20960A (en) 2003-02-28
RS51201B (en) 2010-12-31
AU779214B2 (en) 2005-01-13
US20160051657A1 (en) 2016-02-25
CZ302662B6 (en) 2011-08-24
YU37402A (en) 2005-06-10
AU1874101A (en) 2001-06-04
CZ20021771A3 (en) 2002-11-13
PT1272216E (en) 2010-09-14
CA2394843A1 (en) 2001-05-31
US20080175865A1 (en) 2008-07-24

Similar Documents

Publication Publication Date Title
US20180161414A1 (en) Vaccine comprising lactobacillus strains for treating prostate inflammation and benign prostate hyperplasias
EP0681479B1 (en) Immunotherapeutic composition
CN1602199B (en) Preparations of gram-positive bacteria for the treatment of diseases involving immune disorders
US20070172499A1 (en) Immunotherapy for humans
CN103157108B (en) Immune modulator composition and pharmaceutical composition thereof and application
JPH05508407A (en) Pasteurella multocida toxoid vaccine
WO2010031883A1 (en) Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
CN114364396B (en) Application of Pseudomonas aeruginosa vaccine in the treatment of burn and scald infections
US20220370588A1 (en) Application of pseudomonas aeruginosa vaccine in treating infection associated with burn or scald injury
RU2815387C1 (en) Corynebacterium pseudotuberculosis bacteria strain, intended for producing mono- or polyvalent immunogenic compositions, aimed at specific prevention of caseous lymphadenitis (pseudotuberculosis) of small cattle
Bizzini et al. Experimental and Clinical Results
CN121780403A (en) An enhanced Brucella outer membrane vesicle, its preparation method and application
KR20240163211A (en) Novel Corynebacterium pseudotuberculosis strain isolated from caseous lymphadenitis infected goat and vaccine composition for preventing caseous lymphadenitis comprising the same
US2040794A (en) Common-cold antigen
CA2154689C (en) Improved immunotherapeutic composition
Maktoof et al. EVALUATION OF THE ROLE OF CHITOSAN IN THE IMMUNOPATHOLOGY OF OSTEOMYELITIS IN DIABETIC RABBITS
Packard et al. THE PRESENT STATUS OF SERUM THERAPY.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-374/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 149779

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2002-1771

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002 200200663

Country of ref document: RO

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2394843

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 7382002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2000981507

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 18741/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200020063

Country of ref document: SI

WWE Wipo information: entry into national phase

Ref document number: 200200602

Country of ref document: EA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2002-1771

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000981507

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 18741/01

Country of ref document: AU